Tags:

Celgene Corporation


A securities class action has been filed against Celgene Corporation (CELG) on behalf of all former Celgene Corporation (“Celgene”) shareholders that received Contingent Value Rights (“CVRs”) in exchange for their Celgene shares pursuant to the Bristol-Myers Squibb Company (“Bristol” or “Bristol Myers”) acquisition of Celgene on November 20, 2019.  This case has been filed in the USDC – S.D.N.Y.

The Complaint alleges that the joint definitive proxy statement filed by the Defendants on February 22, 2019 with the SEC to solicit shareholder approval of the Merger of Celgene and Bristol contained materially false and misleading statements and/or omitted material facts concerning the CVRs and the development and approval of a cancer therapy named Liso-cel.

Tags:

Securities